List view / Grid view
What if familiar lab formats could be redesigned to remove the weak points in permeability and absorbance testing? This article explores how design choices in common consumables can improve both speed and reproducibility in early-stage research.
Developing robust potency assays for Antibody-Drug Conjugates (ADCs) is crucial for ensuring their clinical success, but designing assays that meet both technical and regulatory standards is challenging. Here, Abzena’s CSO Campbell Bunce explores the complexities of assay development and the importance of ensuring accuracy, consistency and regulatory alignment for ADCs…
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.
Gene therapy’s progress depends on reliable supply chains and efficient manufacturing. In this episode, we explore the challenges and strategies involved in plasmid production - an essential component in advancing life-changing therapies.
Chief Scientific Officer at Solvias reveals how CROs are overcoming manufacturing challenges and harnessing AI to fast-track the development of groundbreaking cell and gene therapies.
Antibody-drug conjugates (ADCs) are transforming cancer therapy by enabling targeted drug delivery with minimised side effects, but their complex structure presents unique challenges in bioanalysis. This article explores cutting-edge strategies for optimising ADC evaluation, from quantifying drug-to-antibody ratios (DAR) to overcoming hurdles like payload interference and stability.
Three-dimensional (3D) models are reshaping pre-clinical drug development by providing more accurate insights into drug safety and efficacy. Explore how these advanced in vitro systems help improve predictions and reduce the risk of failure in early-stage drug discovery.
Refeyn's new software automates mass photometry workflows, delivering faster and more consistent results for bioanalytical applications.
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
Viral capsid assembly and quality are key factors in gene therapy success and safety. Here, Dr Chelsea Pratt explores how cutting-edge tools are enabling scientists to tackle these challenges and improve patient outcomes.
The era of precision medicine demands more rigorous biomarker validation methods. While ELISA has long been the gold standard, advanced technologies such as LC-MS/MS and Meso Scale Discovery (MSD) offer superior precision, sensitivity and efficiency. Here, Prasad Lakshmanan Selvaraj, Director of Technical Review at Sannova, explains that by embracing these…
HIV-Tocky, a new viral reporter system, uncovers the molecular mechanisms of provirus silencing and expression.
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
Learn more about Euretos computational disease model and how it predicts many of the known drug targets for RA.
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
